We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941.
- Authors
Lange, Beverly J; Dinndorf, Patricia; Smith, Franklin O; Arndt, Carola; Barnard, Dorothy; Feig, Stephen; Feusner, James; Seibel, Nita; Weiman, Margie; Aplenc, Richard; Gerbing, Robert; Alonzo, Todd A
- Abstract
Randomized comparisons of idarubicin (IDA) with daunorubicin (DNR) show that in adults with acute myeloid leukemia (AML), IDA achieves higher remission rates and longer remission durations. In Children's Cancer Group Pilot Study CCG-2941, we assessed toxicity and feasibility of substituting 4 mg of DNR with 1 mg of IDA in intensive-timing daunorubicin-based induction therapy (DNR/DNR) used in CCG-2891.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Vol 22, Issue 1, p150
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2004.04.016